JP2006510618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510618A5 JP2006510618A5 JP2004553852A JP2004553852A JP2006510618A5 JP 2006510618 A5 JP2006510618 A5 JP 2006510618A5 JP 2004553852 A JP2004553852 A JP 2004553852A JP 2004553852 A JP2004553852 A JP 2004553852A JP 2006510618 A5 JP2006510618 A5 JP 2006510618A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- phenyl
- pain
- oxo
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 52
- 208000002193 Pain Diseases 0.000 claims 33
- 230000036407 pain Effects 0.000 claims 29
- 239000000651 prodrug Substances 0.000 claims 28
- 229940002612 prodrug Drugs 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 206010002091 Anaesthesia Diseases 0.000 claims 12
- 230000037005 anaesthesia Effects 0.000 claims 12
- 230000037396 body weight Effects 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- BEQZHFIKTBVCAU-LBPRGKRZSA-N (2s)-2-amino-2-(2-chlorophenyl)cyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(N)CCCCC1=O BEQZHFIKTBVCAU-LBPRGKRZSA-N 0.000 claims 8
- BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 230000003444 anaesthetic effect Effects 0.000 claims 8
- 230000000202 analgesic effect Effects 0.000 claims 8
- 229960003299 ketamine Drugs 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 7
- LNJROULPSUMIKM-UHFFFAOYSA-N benzyl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound ClC1=CC=CC=C1C1(NC(=O)OCC=2C=CC=CC=2)C(=O)CCCC1 LNJROULPSUMIKM-UHFFFAOYSA-N 0.000 claims 5
- HCZIRBMTVSUBQG-UHFFFAOYSA-N butyl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C1(NC(=O)OCCCC)CCCCC1=O HCZIRBMTVSUBQG-UHFFFAOYSA-N 0.000 claims 5
- JSMLYOVUWZPMRT-UHFFFAOYSA-N ethyl 2-[[1-(2-chlorophenyl)-2-oxocyclohexyl]amino]acetate Chemical compound C=1C=CC=C(Cl)C=1C1(NCC(=O)OCC)CCCCC1=O JSMLYOVUWZPMRT-UHFFFAOYSA-N 0.000 claims 5
- NFEDRUZLYVEQFI-UHFFFAOYSA-N ethyl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C1(NC(=O)OCC)CCCCC1=O NFEDRUZLYVEQFI-UHFFFAOYSA-N 0.000 claims 5
- VRURQRAMHBAFOK-UHFFFAOYSA-N phenyl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound ClC1=CC=CC=C1C1(NC(=O)OC=2C=CC=CC=2)C(=O)CCCC1 VRURQRAMHBAFOK-UHFFFAOYSA-N 0.000 claims 5
- BJHGQFPMVBHYLW-UHFFFAOYSA-N propan-2-yl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C1(NC(=O)OC(C)C)CCCCC1=O BJHGQFPMVBHYLW-UHFFFAOYSA-N 0.000 claims 5
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 4
- 208000000003 Breakthrough pain Diseases 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 4
- 230000035606 childbirth Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- -1 azaaryl Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000002270 dispersing agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000007975 buffered saline Substances 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42679302P | 2002-11-18 | 2002-11-18 | |
| PCT/US2003/036789 WO2004045601A1 (en) | 2002-11-18 | 2003-11-18 | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510618A JP2006510618A (ja) | 2006-03-30 |
| JP2006510618A5 true JP2006510618A5 (https=) | 2007-01-25 |
Family
ID=32326427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553852A Withdrawn JP2006510618A (ja) | 2002-11-18 | 2003-11-18 | ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040248964A1 (https=) |
| EP (2) | EP2027854A1 (https=) |
| JP (1) | JP2006510618A (https=) |
| AT (1) | ATE432697T1 (https=) |
| AU (1) | AU2003291037A1 (https=) |
| CA (1) | CA2506615A1 (https=) |
| DE (1) | DE60327883D1 (https=) |
| NZ (1) | NZ540282A (https=) |
| WO (1) | WO2004045601A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0523031D0 (en) * | 2005-11-11 | 2005-12-21 | Yaupon Therapeutics | Enhancement of morphine analgesia by s(-)-norketamine |
| US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
| US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
| US8710070B2 (en) * | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| EP2334176A4 (en) | 2008-09-27 | 2012-05-02 | Taraxos Inc | TOPICAL FORMULATIONS FOR THE TREATMENT OF NERVE DISEASES |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| PL3214066T3 (pl) * | 2009-07-16 | 2024-07-01 | Specialty Operations France | Sposób wytwarzania fluoromrówczanów fluoroalkilu |
| EP3904332B1 (en) * | 2011-10-14 | 2024-12-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
| US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
| WO2014020155A1 (en) * | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| EA201590697A1 (ru) * | 2012-10-08 | 2015-09-30 | Окленд Юнисервисиз Лимитед | Производные кетамина |
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| JP6462663B2 (ja) | 2013-04-12 | 2019-01-30 | アイカーン スクール オブ メディシン アット マウント シナイ | 心的外傷後ストレス障害を処置するための方法 |
| SI3043785T1 (sl) | 2013-09-13 | 2022-02-28 | National University Corporation Chiba University | Uporaba R-ketamina in njegove soli kot farmacevtska sredstva |
| WO2015101693A1 (es) * | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas |
| CA2936809A1 (en) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| CN107208133A (zh) | 2014-09-15 | 2017-09-26 | 詹森药业有限公司 | 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法 |
| AU2015343083B2 (en) * | 2014-11-04 | 2020-07-23 | Acadia Pharmaceuticals Inc. | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods |
| BR112017013311B1 (pt) | 2014-12-23 | 2022-05-31 | Acelrx Pharmaceuticals, Inc | Aparelho para a dispensação de formas de dosagem via oral e transmucosal |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| WO2016186968A1 (en) * | 2015-05-15 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating motor disorders |
| AU2016280161B2 (en) * | 2015-06-19 | 2019-02-21 | Harrow Ip, Llc | Pharmaceutical compositions for anesthesiological applications |
| US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US11111210B2 (en) | 2015-11-18 | 2021-09-07 | Spirify Pharma Inc. | Phenyl cyclohexanone derivatives and methods of making and using them |
| US11827606B2 (en) | 2015-11-18 | 2023-11-28 | Spirify Pharma Inc. | Phenyl cyclohexanone derivatives and methods of making and using them |
| JP7110094B2 (ja) * | 2015-11-19 | 2022-08-01 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | 医薬化合物のアミンプロドラッグ |
| US11006661B2 (en) * | 2016-08-15 | 2021-05-18 | Mamood Valadi | Cigarette-like device for administration of substances |
| US9963435B2 (en) | 2016-08-31 | 2018-05-08 | Dart Neuroscience, Llc | Compounds for therapeutic use |
| KR102471059B1 (ko) * | 2016-08-31 | 2022-11-25 | 다트 뉴로사이언스, 엘엘씨 | 장애의 치료를 위한 하이드록시노르케타민 유도체 |
| US20190240184A1 (en) * | 2016-10-27 | 2019-08-08 | National University Corporation Chiba University | Pharmaceutical applications for (s)-norketamine and salts thereof |
| CN115109116A (zh) | 2017-08-17 | 2022-09-27 | 凯瑞康宁生物工程（武汉）有限公司 | 活性氧清除剂衍生物的制备及用途 |
| WO2019041361A1 (en) | 2017-09-04 | 2019-03-07 | Xw Laboratories, Inc. | PREPARATION AND USE OF A REACTIVE OXYGEN SPECIES TRAPPER |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| WO2019065900A1 (ja) * | 2017-09-27 | 2019-04-04 | 国立大学法人千葉大学 | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| MX2020006650A (es) | 2017-12-22 | 2020-11-06 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| IL275968B2 (en) * | 2018-01-10 | 2024-07-01 | Xwpharma Ltd | Prodrugs of ketamine, compositions and uses thereof |
| JP7548669B2 (ja) | 2018-02-15 | 2024-09-10 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197B2 (en) | 2018-05-04 | 2024-12-19 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| MX2021010683A (es) | 2019-03-05 | 2021-12-10 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| CN110538169B (zh) * | 2019-05-24 | 2020-08-25 | 北京大学深圳研究生院 | 一种长效化合物在制备药物中的应用 |
| US11753378B2 (en) * | 2021-04-19 | 2023-09-12 | Zevra Therapeutics, Inc. | Ketamine compounds and processes for making and using them |
| WO2023018966A1 (en) | 2021-08-13 | 2023-02-16 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
| EP4289815A1 (en) | 2022-06-10 | 2023-12-13 | Pcas | Crystalline forms of norketamine |
| WO2024044355A2 (en) * | 2022-08-25 | 2024-02-29 | 1/1The Trustees Of Columbia University In The City Of New York | Compositions and methods for the treatment of alzheimer's disease and other neurogenerative disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US713A (en) | 1838-04-25 | Improvement in many-chambered-cylinder fire-arms | ||
| US5407A (en) | 1847-12-28 | Fence | ||
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4879119A (en) | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
| US4671953A (en) | 1985-05-01 | 1987-06-09 | University Of Utah Research Foundation | Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| EP0431519B1 (en) | 1989-12-04 | 1994-06-15 | G.D. Searle & Co. | System for transdermal albuterol administration |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
| SE9203743D0 (sv) | 1992-12-11 | 1992-12-11 | Astra Ab | Efficient use |
| US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| ES2237767T3 (es) | 1995-04-14 | 2005-08-01 | Nektar Therapeutics | Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada. |
| WO1997007750A1 (en) * | 1995-08-30 | 1997-03-06 | Weg Stuart L | Administration of ketamine to manage pain and to reduce drug dependency |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| EP1829539A3 (en) * | 1996-11-05 | 2008-02-20 | HEADEXPLORER ApS | A method for treating tension-type headache |
| WO1998058633A2 (en) | 1997-06-23 | 1998-12-30 | Queen's University At Kingston | Microdose therapy of vascular conditions by no donors |
| US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
| US6406745B1 (en) | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
| US6565888B1 (en) | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
| US20050148673A1 (en) * | 2002-07-11 | 2005-07-07 | Harbut Ronald E. | Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
-
2003
- 2003-11-18 AU AU2003291037A patent/AU2003291037A1/en not_active Abandoned
- 2003-11-18 JP JP2004553852A patent/JP2006510618A/ja not_active Withdrawn
- 2003-11-18 WO PCT/US2003/036789 patent/WO2004045601A1/en not_active Ceased
- 2003-11-18 NZ NZ540282A patent/NZ540282A/en unknown
- 2003-11-18 EP EP08168894A patent/EP2027854A1/en not_active Withdrawn
- 2003-11-18 EP EP03783623A patent/EP1567145B1/en not_active Expired - Lifetime
- 2003-11-18 AT AT03783623T patent/ATE432697T1/de not_active IP Right Cessation
- 2003-11-18 US US10/714,643 patent/US20040248964A1/en not_active Abandoned
- 2003-11-18 DE DE60327883T patent/DE60327883D1/de not_active Expired - Fee Related
- 2003-11-18 CA CA002506615A patent/CA2506615A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006510618A5 (https=) | ||
| EP1567145B1 (en) | Analgesic uses of (s)-norketamine | |
| RU2438660C2 (ru) | Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей | |
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| JP2007507494A5 (https=) | ||
| JP2003509349A5 (https=) | ||
| JP2013511496A5 (https=) | ||
| ES3037078T3 (en) | Isoxazoline compounds for use in treating demodicosis | |
| JP2001526218A5 (https=) | ||
| JP2009543860A5 (https=) | ||
| JP2008510758A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2009530393A5 (https=) | ||
| CA2303815A1 (en) | N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain | |
| JP2003519228A5 (https=) | ||
| JP2007515476A5 (https=) | ||
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| AU2008259864C1 (en) | Methods and compositions for administration of Oxybutynin | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| JP2002544227A5 (https=) | ||
| JP2022508217A (ja) | Ｔａｓｋ－１およびｔａｓｋ－３チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用 | |
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы | |
| JP2006501207A5 (https=) | ||
| RU2010147881A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА | |
| RU2011105463A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА |